Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium ophthalmic solution is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. diclofenac sodium ophthalmic solution is contraindicated in patients who are hypersensitive to any component of the medication.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jardiance is not recommended in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . jardiance is likely to be ineffective in this setting based upon its mechanism of action. - hypersensitivity to empagliflozin or any of the excipients in jardiance, reactions such as angioedema have occurred [see warnings and precautions (5.7)] . - patients on dialysis [see use in specific population

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - dulaglutide (unii: wtt295hsy5) (dulaglutide - unii:wtt295hsy5) - trulicity® is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. limitations of use trulicity: - has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - should not be used in patients with type 1 diabetes mellitus. - has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see warnings and precautions (5.6)] . trulicity is contraindicated in patients with: - personal or family history of medullary thyroid carcino

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - dulaglutide (unii: wtt295hsy5) (dulaglutide - unii:wtt295hsy5) - trulicity® is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. limitations of use trulicity: - has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - should not be used in patients with type 1 diabetes mellitus. - has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see warnings and precautions (5.6)] . trulicity is contraindicated in patients with: - personal or family history of medullary thyroid carcino

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jardiance is not recommended in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . jardiance is likely to be ineffective in this setting based upon its mechanism of action. - hypersensitivity to empagliflozin or any of the excipients in jardiance, reactions such as angioedema have occurred [see warnings and precautions (5.7)] . - patients on dialysis [see use in specific population

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: - patients with known hypersensitivity to triazolam, any of component of triazolam tablets, or other benzodiazepines. reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. - concomitant administration of strong cytochrome p450 (cyp 3a) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [ see warnings and precautions (5.8), drug interactions (7.1) ] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to triazolam during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for other psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermed

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - sitagliptin phosphate (unii: ts63ew8x6f) (sitagliptin - unii:qfp0p1dv7z), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - janumet® xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use janumet xr should not be used in patients with type 1 diabetes mellitus. janumet xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using janumet xr. [see warnings and precautions (5.2).] janumet xr is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis. - history of a serious hypersensitivity reaction to janumet xr, sitagliptin, or metformin such as anaphylaxis or angioedema. [see warnings and precautions (5.7); adverse reactions (6.2). ] risk summary the limited available data with janumet xr in pregnant women are not sufficient to inform a drug-associated risk for major b

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - sitagliptin phosphate (unii: ts63ew8x6f) (sitagliptin - unii:qfp0p1dv7z), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - janumet® xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use janumet xr should not be used in patients with type 1 diabetes mellitus. janumet xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using janumet xr. [see warnings and precautions (5.2).] janumet xr is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis. - history of a serious hypersensitivity reaction to janumet xr, sitagliptin, or metformin such as anaphylaxis or angioedema. [see warnings and precautions (5.7); adverse reactions (6.2). ] risk summary the limited available data with janumet xr in pregnant women are not sufficient to inform a drug-associated risk for major b

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - mometasone furoate 200 ug - dulera is indicated for the twice-daily treatment of asthma in patients 12 years of age and older. dulera should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use: - dulera is not indicated for the relief of acute bronchospasm. dulera is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. dulera is contraindicated in patients with known hypersensitivity to mometasone furoate, formoterol fumarate, or any of the ingredients in dulera [see warnings and precautions (5.10)] . risk summary there are no randomized clinical studies of dulera, mometasone furoate, or formoterol fumarate in pregnant women. there are clinical considerations with the use of dulera in pregnant women [see clinical considerations] . animal

Amerika Serikat - Inggris - NLM (National Library of Medicine)

a-s medication solutions - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 500 mg - mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids. mycophenolate mofetil intravenous is an alternative dosage form to mycophenolate mofetil tablets, capsules and oral suspension. mycophenolate mofetil intravenous should be administered within 24 hours following transplantation. mycophenolate mofetil intravenous can be administered for upto 14 days; patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. mycophenolate mofetil intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).